Login to Your Account

Xtuit goes 'micro' in cancer, fibrosis with $22M series A

By Marie Powers
News Editor

Thursday, June 11, 2015
Four years after its launch, Xtuit Pharmaceuticals Inc. came out of virtual mode with a $22 million series A that should suffice to advance its lead candidates in oncology and liver fibrosis through human proof-of-concept studies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription